Latest news with #JensFrauenfeld
Korea Herald
2 days ago
- Business
- Korea Herald
Daewoong partners with Sweden's Salipro to boost drug discovery
Daewoong Pharmaceutical on Wednesday announced a strategic research partnership with Swedish biotech company Salipro Biotech to jointly develop next-generation therapeutics targeting membrane proteins. Under the agreement, Salipro will provide Daewoong access to its proprietary Salipro Platform, a technology that stabilizes membrane proteins in a near-native environment, making them more accessible for drug discovery. Membrane proteins are involved in essential cellular functions and account for over 60 percent of known drug targets, yet their structural instability in lab conditions has long been a barrier to research. The partnership is Salipro's first with a Korean company and follows previous collaborations with major pharmaceutical firms including Boehringer Ingelheim, Sanofi and Sumitomo. Daewoong views the alliance as a key step in its open innovation strategy, aiming to bolster its global competitiveness and lay the groundwork for potential overseas licensing deals. 'Our partnership with Daewoong marks Salipro's first collaboration with a Korean company, making it especially meaningful,' Jens Frauenfeld, CEO of Salipro Biotech, stated. 'The Salipro platform enables research on previously inaccessible target proteins and is expected to unlock new possibilities in global innovative drug development.' Park Seong-soo, CEO of Daewoong Pharmaceutical, added, 'We expect that the Salipro platform will enhance our access to challenging membrane protein targets and accelerate our drug discovery efforts. Through an open collaboration strategy, we will continue to develop globally competitive new drugs.'
Korea Herald
2 days ago
- Business
- Korea Herald
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product.
Yahoo
2 days ago
- Business
- Yahoo
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd.
Yahoo
14-03-2025
- Business
- Yahoo
Boehringer Ingelheim and Salipro enter drug discovery partnership
Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The partnership is set to progress the discovery and development of new therapeutic solutions that target G protein-coupled receptors (GPCRs), transporters and ion channels, which are crucial in cardio-renal-metabolic and mental health diseases. Salipro platform technology will be leveraged in the partnership. This platform stabilises membrane proteins in their native states, facilitating their usage in drug discovery programmes. It brings together Salipro Biotech's expertise and its platform technology for stabilising targets from the drug discovery programmes of Boehringer, enabling and expediting the development of new therapeutics. Boehringer plans to carry out structural and biophysical studies which include cryo-electron microscopy on its pipeline targets to detect potential candidates. Boehringer will provide Salipro with research and option payments. Salipro is qualified for success-based milestone payments contingent on the developmental outcomes produced by Boehringer under this partnership. Salipro Biotech CEO Jens Frauenfeld stated: 'We are excited to collaborate with the innovative teams at Boehringer Ingelheim. 'By combining our Salipro platform technology with Boehringer Ingelheim's expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.' The Swedish company has established several research partnerships with pharmaceutical and biotech entities. It aims to expedite drug discovery via in-house and collaborated pipelines. In December 2024, the company announced the receipt of patents granted for its Salipro platform technology in both Australia and Singapore. It also facilitates drug discovery programmes, which include screening small molecule drugs, structure-based drug design and antibody discovery. In October 2023, Salipro Biotech entered a multi-target antibody research agreement with Icosagen, a biotech company. "Boehringer Ingelheim and Salipro enter drug discovery partnership" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
13-03-2025
- Business
- Yahoo
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim's drug discovery programs to enable and accelerate the development of novel therapeutics. STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases. The partnership leverages Salipro Biotech's proprietary Salipro® platform technology, which stabilises membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro®-technology to identify potential therapeutic candidates. Under the terms of the agreement, Salipro Biotech will receive research payments, option payments and is eligible for downstream success-based milestone payments based on developmental results generated by Boehringer Ingelheim under this collaboration. 'We are excited to collaborate with the innovative teams at Boehringer Ingelheim,' said Jens Frauenfeld, CEO of Salipro Biotech. 'By combining our Salipro® platform technology with Boehringer Ingelheim's expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.' About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilisation of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. Press contact:Salipro Biotech ABJens FrauenfeldCEO+46 (0)70 052 in to access your portfolio
